Abstract
Forty-six patients with recurrent metastatic breast cancer were treated with a combination chemotherapy including doxorubicin and mitomycin C. Myocardial contractility was monitored by means of echocardiography. During therapy there was a progressive deterioration of myocardial function, and this phenomenon was found to be linearly correlated to the cumulative dose of doxorubicin. Six patients (13.8%) developed congestive heart failure during therapy; it occurred after the median cumulative dose of 322 mg/m2 (range 135–472). Possible risk factors of cardiomyopathy could be identified in only two patients. These results suggest that mitomycin C could enhance the cardiotoxicity of doxorubicin.
Similar content being viewed by others
References
Blum R H, Carter S K: Adriamycin: a new anticancer drug with significant clinical activity.Ann Intern Med 80, 249 (1974).
Ugoretz R F: Cardiac effects of doxorubicin therapy of neoplasms.J Am Med Assoc 236, 295 (1976).
Bristow M R, Mason J W, Billingham M E, Daniels J R: Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization.Ann Intern Med 88, 168 (1978).
Von Hoff D D, Layard M W, Basa P, Davis H L Jr, Von Hoff A L, Rozencweig M, Muggia F M: Risk factors for doxorubicin-induced congestive heart failure.Ann Int Med 91, 710 (1979).
Kinsella T J, Ahmann D L, Giuliani E R, Lie J T: Adriamycin cardiotoxicity in stage IV breast cancer: possible enhancement with prior left chest radiation therapy.Int J Radiat Oncol Biol Phys 5, 1997 (1979).
Minow R A, Benjamin R S, Lee E T, Gottlieb J A: Adriamycin cardiomyopathy: risk factors.Cancer 39, 1397 (1977).
Merrill J P, Greco F A, Zimbler H, Brereton H D, Lamberg J D, Pomeroy T C: Ariamycin and radiation synergistic cardiotoxicity.Ann Intern Med 82, 122 (1975).
Praga C, Beratta G, Vigo P L, Lenan G R, Pollini C, Bonadonna G, Canetta R, Castellani R, Villa E, Gallagher C G, von Melchner H, Hayat M, Ribaud P, De Wasch G, Mattsson W, Heinz R, Waldner R, Kolaric K, Buehner R, Ten Bokkel-Huynink W, Perevodchikova N I, Manziuk L A, Senn H J, Mayr A C: Adriamycin cardiotoxicity: a survey of 1273 patients.Cancer Treat Rep 63, 827 (1979).
Prout M N, Richards M J S, Chung K J, Joo P, Davis H L Jr: Adriamycin cardiotoxicity in children: case reports. literature review and risk factors.Cancer 39, 62 (1977).
Kushner J P, Hansen V L, Hammar S P: Cardiomyopathy after widely separated courses of adriamycin.Cancer 36, 1577 (1975).
Minow R A, Benjamin R S, Gottlieb J A: Adriamycin (NSC 123–127) cardiomyopathy: an overview with determination of risk factors.Cancer Chemother Rep 6, 195 (1975).
O’Connell T X, Berenbaum M C: Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide.Cancer Research 34, 1586 (1974).
Bitran J D: Doxorubicin cardiotoxicity and melphalan.Ann Int med 95, 243 (1981).
Buzdar A U, Legha S S, Tashima C K, Hortobagyi G N, Yong Yap H, Krutchik A N, Luna M A, Blumenschein G R: Adriamycin and mitomycin C: possible synergistic cardiotoxicity.Cancer Treat Rep 62, 1005 (1978).
Jain K, Wittes R, Benedetto P, Kaufman R, Currie V, Hakes T, Bosl G: A randomized comparison of weekly (arm I) versus monthly (arm II) doxorubicin in combination with mitomycin C in advanced breast cancer (abstract).Proceedings ASCO, San Diego, May, p. 109 (1983).
Creech R H, Dayal H, Catalano R B, Dierks K, Shah M K: Combination doxorubicin-mitomycin therapy for hormonal and CMF-refractory metastatic breast cancer (abstract).Proceeding ASCO, Toronto, May, p. 126 (1984).
Knapp W H: Relationship between mean velocity of circumferential fiber shortening (VCF) and heart rate. The diagnostic value of a normalization of VCF heart rate.J Clin Ultrasound 6, 10 (1978).
Dinddogru A, Barcos M, Henderson E S, Wallace H J: Electrocardiographic changes following adriamycin treatment. Med Pediat Oncol5, 65 (1978).
Villani F, Lacaita G, Genitoni V, Comazzi R, Guindani A: Comparative cardiotoxity of different anthracycline derivatives.Drugs Under Exp Clin Res 9, 781 (1983).
Villani F, Comazzi R, Lacaita G, Genitoni V, Guindani A, Martini A: Preliminary echocardiographic and polygraphic evaluation of cardiac toxicity of 4′-epi-doxorubicin.Int J Clin Pharmacol Ther Toxicol 21, 203 (1983).
Bloom K R, Bini R M, Williams C M, Sonley M J, Gribbin M A: Echocardiography in adriamycin cardiotoxicity.Cancer 41, 1265 (1978).
Villani F, Beretta G, Guindani A, Pagnoni A, Vivarelli S: Valutazione policardiografica della cardiotossicità da adriamicina.G Ital Chemioter 22, 39 (1975).
Rosi D R, Nogeire C, Brown B, Ali M, Ewer M, Samuels M: 5-Fluorouracil, adriamycin and mitomycin-C (H1-FAM) chemotherapy for adenocarcinoma of the lung.Cancer 48, 21 (1981).
Smith F P, Hoth D F, Levin B, Karlin D A, MacDonald J S, Wolley P V, Schein P S: 5-Fluorouracil, adriamycin and mitomycin-C (FAM). Chemotherapy for advanced adenocarcinoma of the pancreas.Cancer 46, 2014 (1980).
MacDonald J S, Schein P S, Wolley P V, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C: 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.Ann Int Med 93, 533 (1980).
Lagothetis C J, von Eschenbach A C, Samuels M L, Trindade A, Johnson D E: Doxorubicin, mitomycin and 5-FU (DMF) in the treatment of hormone resistant stage D prostate cancer: a preliminary report.Cancer Treat Rep 66, 57 (1982).
Crooke S T, Bradner W T: Mitomycin C: a review.Cancer Treat Rep 3, 121 (1976).
Philips F S, Schwartz H S, Sternberg S S: Pharmacology of mitomycin C.Cancer Res 20, 1354 (1960).
Monti E, Bossa R, Galatulas I, Favalli L, Villani F, Piccinini F: Interaction between doxorubicin and mitomycin C on mortality and myocardial contractility in guinea pig.Tumori 69, 113 (1983).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Villani, F., Comazzi, R., Lacaita, G. et al. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. Med. Oncol. & Tumor Pharmacother. 2, 93–97 (1985). https://doi.org/10.1007/BF02934854
Issue Date:
DOI: https://doi.org/10.1007/BF02934854